Short answer:
Tirzepatide’s market share versus dulaglutide is shaped by a mix of clinical, economic, and practical factors:
| Factor | How it matters | Typical trend so far |
|--------|----------------|----------------------|
| Efficacy | Tirzepatide shows a 1–2 % larger HbA1c drop and 1–2 % greater weight loss vs dulaglutide in SURPASS‑5. | Gives tirzepatide an edge for patients who need tighter glucose control and more weight loss. |
| Safety / Tolerability | Both drugs cause GI upset, but tirzepatide’s nausea is slightly more common; dulaglutide is more familiar to clinicians. | May keep dulaglutide preferred by patients sensitive to nausea. |
| Dose & Administration | Once‑weekly injections for both; tirzepatide has a smaller pen with 2 mg‑step increments. | No major difference, but some patients like the smaller syringe. |
| Price & Reimbursement | Tirzepatide (Mounjaro) launched at roughly $0.32–$0.40 per dose; dulaglutide (Trulicity) around $0.25–$0.30 per dose. Payers often put newer agents on higher formulary tiers. | Higher cost of tirzepatide can limit adoption until insurance coverage improves. |
| Formulary & Coverage | Novo Nordisk’s Trulicity is a long‑standing product on many formularies; Eli Lilly’s Mounjaro is newer and sometimes requires prior authorization. | Dulaglutide enjoys easier access in many health plans. |
| Clinical Guidelines | ADA/EASD 2024 guidelines rank dulaglutide (class II) and tirzepatide (class I) similarly for T2DM, but tirzepatide is highlighted for weight‑focused regimens. | Guidelines still favor dulaglutide in many pay‑or‑case settings. |
| Patient Preference & Brand Recognition | Trulicity has been on the market since 2016; patients and prescribers know the brand. Tirzepatide is still building recognition. | Brand familiarity keeps dulaglutide ahead among existing users. |
| Real‑World Evidence (RWE) | RWE for tirzepatide is emerging; dulaglutide has a long track record of safety data. | Clinicians may lean toward dulaglutide until more RWE for tirzepatide is available. |
| Market Penetration & Competition | Tirzepatide competes with semaglutide (Ozempic, Wegovy) and dulaglutide; semaglutide still holds the largest share in GLP‑1 RA market. | Tirzepatide must capture a niche within an already crowded field. |
| Regulatory & Off‑Label Uses | Tirzepatide is FDA‑approved for T2DM and obesity (as of 2023); dulaglutide is approved for T2DM only (weight‑loss uses are off‑label). | Tirzepatide can be marketed for both conditions, potentially expanding its share. |
| Long‑Term Data & Safety | Tirzepatide has less long‑term data compared to dulaglutide’s >5‑year safety track record. | Some prescribers may delay adoption until longer data become available. |
---
Why each factor matters
| Factor | Why it matters |
|--------|----------------|
| Clinical benefit | In real life, a drug that lowers HbA1c and weight more effectively can be a deciding factor, especially for patients with obesity. |
| Side‑effect profile | GI side effects often drive discontinuation. A drug that people can tolerate better will be prescribed more frequently. |
| Cost & insurance | Payers are gatekeepers. Higher out‑of‑pocket costs or strict prior‑auth rules can slow uptake, even for a clinically superior drug. |
| Formulary placement | A drug on a lower tier is easier to obtain; patients are more likely to stay on therapy. |
| Brand familiarity | Clinicians are comfortable with a drug they’ve used for years; switching requires time and confidence. |
| Guidelines | Many prescribers use guidelines as a quick reference; a drug that receives a higher recommendation will get more prescriptions. |
| Real‑world evidence | Outside of trials, real‑world data reassure clinicians about long‑term safety and effectiveness. |
| Competition | In a crowded space, a drug needs to differentiate itself through cost, convenience, or clear clinical advantage. |
| Regulatory status | Approvals for multiple indications (diabetes + obesity) expand the potential patient pool. |
| Long‑term data | For chronic conditions, long‑term safety is paramount; older drugs have a proven track record. |
---
Bottom line
Tirzepatide is clinically compelling—better glycaemic control and weight loss—so it’s poised to capture a growing share, especially among patients who need stronger weight management. However, price, payer hurdles, and brand familiarity currently keep dulaglutide ahead in many markets. As reimbursement becomes smoother, real‑world data accumulate, and the brand gains recognition, tirzepatide’s market share is likely to grow, but it will still be competing against both dulaglutide and semaglutide for the top spot in the GLP‑1 RA arena.